Automation And Biologics Adoption Will Transform Injectable Solutions
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 10 Analysts
Published
17 Jun 25
Updated
15 Aug 25
AnalystHighTarget's Fair Value
US$36.07
37.3% undervalued intrinsic discount15 Aug
US$22.62
1Y
13.1%7D
3.5%